Samsung BioLogics IPO may raise US$2bil

  • Business
  • Wednesday, 05 Oct 2016

SEOUL: Samsung BioLogics Co Ltd, a contract manufacturer of biotech drugs for global pharmaceutical firms, said its initial public offering is expected to raise as much as US$2bil in what is set to be South Korea's third-largest IPO.

The listing is aimed at helping fund an ambitious expansion in production capacity to make it the world's largest contract manufacturer.

The offering of 25% of the company is expected to consist of a new share issue of 11 million shares and the sale of 5.5 million existing shares by Samsung Electronics Co Ltd. With an indicative pricing range of 113,000 won-136,000 won per share, the offering is expected to raise 2.25 trillion won (US$2bil).

BioLogics said 780 billion won of the proceeds will be used for factory investment, while another 400 billion won will be invested in biosimilar drug developer unit Samsung Bioepis. — Reuters

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 0
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

Next In Business News

Trading ideas: KLCCP Stapled Group, Lambo, Teladan Setia, Lotte Chemical Tital, CTOS Digital and Pasukhas
Call for government to rethink its 5G deployment strategy
Superheroes need not apply for BoJ’s top job
Western Digital to get investment from Apollo, Elliott
Pertamina unit to raise US$652mil in IPO
Blackstone-REIT ready to ‘play offence’ with US$14bil
MNC spending a boon for Penang developers
Indonesia’s January inflation rate cools to 5.28% year-on-year
Thai economy may grow 4% this year on tourism
Housing slump deepens from US to China

Others Also Read